A novel pyrido-thieno-pyrimidine derivative activates p53 through induction of phosphorylation and acetylation in colorectal cancer cells

Kang,Mi Ae; Kim,Mi-Sook; Kim,Ji Young; Shin,Young-Joo; Song,Jie-Young; Jeong,Jae-Hoon

doi:10.3892/ijo.2014.2720

A novel pyrido-thieno-pyrimidine derivative activates p53 through induction of phosphorylation and acetylation in colorectal cancer cells

Authors:
- Mi Ae Kang
- Mi-Sook Kim
- Ji Young Kim
- Young-Joo Shin
- Jie-Young Song
- Jae-Hoon Jeong
View Affiliations

Affiliations: Research Center for Radiotherapy, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea, Department of Radiation Oncology, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea
Published online on: October 22, 2014 https://doi.org/10.3892/ijo.2014.2720
Pages: 342-350

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The tumor suppressor p53 plays a key role in regulation of the cell cycle, apoptosis and senescence in response to various stresses. We screened a library of 7920 chemical compounds for the p53 activator and identified N-[2-(dimethylamino)ethyl]-2,3-dimethyl-4-oxo-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-9-carboxamide (PTP), which significantly increased p53-mediated reporter activity in colorectal cancer cells. PTP was found to induce p53 protein and activated transcription of downstream genes, such as p21 and PUMA, in HCT116 cells, leading to growth delay, G1-phase cell cycle arrest, cell senescence and cell death. Proximity ligation assay revealed that PTP weakened the interaction between p53 and murine double minute 2 (MDM2) in situ, thereby inhibiting MDM2-mediated p53 degradation. Although DNA damage has been known to promote phosphorylation of p53 and MDM2, thereby preventing their interaction and stabilizing p53, PTP did not cause DNA damage or activate any DNA damage response signaling. Instead, phosphorylation of p53 was mediated by Erk1/2 MAP kinase. In addition, PTP induced acetylation of p53 at Lys382 in a p300-dependent manner, but sirtuin (SIRT)1 and histone deacetylase (HDAC)1, a well-known p53-regulating deacetylase, were not involved. In the present study, the novel anticancer agent PTP was shown to cause the accumulation of p53 by inducing multiple post-translational modifications, as well as cell cycle arrest, senescence and cell death.

View Figures

View References

1	Vousden KH: p53: Death Star. Cell. 103:691–694. 2000. View Article : Google Scholar : PubMed/NCBI
2	Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
3	Juven T, Barak Y, Zauberman A, George DL and Oren M: Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene. 8:3411–3416. 1993.PubMed/NCBI
4	Barak Y, Juven T, Haffner R and Oren M: mdm2 expression is induced by wild type p53 activity. EMBO J. 12:461–468. 1993.PubMed/NCBI
5	Miyashita T, Harigai M, Hanada M and Reed JC: Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 54:3131–3135. 1994.PubMed/NCBI
6	Banin S, Moyal L, Shieh SY, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y and Ziv Y: Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 281:1674–1677. 1998. View Article : Google Scholar : PubMed/NCBI
7	Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C and Abraham RT: A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 13:152–157. 1999. View Article : Google Scholar : PubMed/NCBI
8	Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 8:282–288. 2002. View Article : Google Scholar : PubMed/NCBI
9	Miyachi M, Kakazu N, Yagyu S, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, Tsuchiya K, Iehara T and Hosoi H: Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res. 15:4077–4084. 2009. View Article : Google Scholar : PubMed/NCBI
10	Dai F, Chen Y, Song Y, Huang L, Zhai D, Dong Y, Lai L, Zhang T, Li D, Pang X, Liu M and Yi Z: A natural small molecule Harmine inhibits angiogenesis and suppresses tumour growth through activation of p53 in endothelial cells. PLoS One. 7:e521622012. View Article : Google Scholar : PubMed/NCBI
11	Zhang Q, Zeng SX, Zhang Y, Zhang Y, Ding D, Ye Q, Meroueh SO and Lu H: A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol Med. 4:298–312. 2012. View Article : Google Scholar : PubMed/NCBI
12	Jain KS, Chitre TS, Miniyar PB, Kathiravan MK, Bendre VS, Veer VS, Shahane SR and Shishoo CJ: Biological and medicinal significance of pyrimidines. Curr Sci. 90:793–803. 2006.
13	Zhang N, Ayral-Kaloustian S, Nguyen T, Hernandez R and Beyer C: 2-Cyanoaminopyrimidines as a class of antitumor agents that promote tubulin polymerization. Bioorg Med Chem Lett. 17:3003–3005. 2007. View Article : Google Scholar : PubMed/NCBI
14	Cocco MT, Congiu C, Lilliu V and Onnis V: Synthesis and in vitro antitumoral activity of new hyrazinopyriminide-5-carbonitrile derivatives. Bioorg Med Chem. 14:366–372. 2006. View Article : Google Scholar : PubMed/NCBI
15	Cocco MT, Congiu C, Lilliu V and Onnis V: Synthesis of new N-(2-(trifluoromethyl)pyridine-yl)anthranilic acid derivatives and their evaluation as anticancer agents. Bioorg Med Chem Lett. 14:5787–5791. 2004. View Article : Google Scholar : PubMed/NCBI
16	Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical stratagies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
17	Lim MJ, Ahn JY, Han Y, Yu CH, Kim MH, Lee SL, Lim DS and Song JY: Acriflavine enhances radiosensitivity of colon cancer cells through endoplasmic reticulum stress-mediated apoptosis. Int J Biochem Cell Biol. 44:1214–1222. 2012. View Article : Google Scholar
18	Harris SL and Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene. 24:2899–2908. 2005. View Article : Google Scholar : PubMed/NCBI
19	Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature. 387:296–299. 1997. View Article : Google Scholar : PubMed/NCBI
20	Demidenko ZN, Korotchkina LG, Gudkov AV and Blagosklonny MV: Paradoxical suppression of cellular senescence by p53. Proc Natl Acd Sci USA. 107:9660–9664. 2010. View Article : Google Scholar : PubMed/NCBI
21	Hofseth LJ, Hussain SP and Harris CC: p53: 25 years after its discovery. Trends Pharmacol. 25:177–181. 2004.
22	Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV and Blagosklonny MV: The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany, NY). 2:344–352. 2010.PubMed/NCBI
23	Melnikova VO, Santamaria AB, Bolshakov SV and Ananthaswamy HN: Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase. Oncogene. 22:5958–5966. 2003. View Article : Google Scholar : PubMed/NCBI
24	Persons DL, Yazlovitskaya EM and Pelling JC: Effect of extra-cellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem. 275:35778–35785. 2000. View Article : Google Scholar : PubMed/NCBI
25	She QB, Chen N and Dong Z: ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J Biol Chem. 275:20444–20449. 2000. View Article : Google Scholar : PubMed/NCBI
26	Kubbutat MH, Jones SN and Vousden KH: Regulation of p53 stability by Mdm2. Nature. 387:299–303. 1997. View Article : Google Scholar : PubMed/NCBI
27	Maltzman W and Czyzyk L: UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol. 4:1689–1694. 1984.PubMed/NCBI
28	Ashcroft M, Taya Y and Vousden KH: Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol. 20:3224–3233. 2000. View Article : Google Scholar : PubMed/NCBI
29	Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E and Yao TP: p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20:1331–1340. 2001. View Article : Google Scholar : PubMed/NCBI
30	Kuroda T, Murayama A, Katagiri N, Ohta Y, Fujita E, Masumoto H, Ema M, Takahashi S, Kimura K and Yanagisawa J: RNA content in the nucleolus alters p53 acetylation via MYBBP1A. EMBO J. 30:1054–1066. 2011. View Article : Google Scholar : PubMed/NCBI
31	Barneda-Zahonero B and Parra M: Histone deacetylases and cancer. Mol Oncol. 6:579–589. 2012. View Article : Google Scholar
32	Vaziri H, Dessain SK, Eaton EN, Imai SI, Frye RA, Pandita TK, Guarente L and Weinberg RA: hSIR2^SIRT1 functions as an NAD-dependent p53 deacetylation. Cell. 107:149–159. 2001. View Article : Google Scholar